Skip to main content
. Author manuscript; available in PMC: 2020 Jun 1.
Published in final edited form as: Hepatology. 2019 Mar 13;69(6):2518–2532. doi: 10.1002/hep.30528

Figure 1. polyIC inhibits liver tumor initiation but not progression.

Figure 1.

(A) The scheme of experimental procedure for polyIC treatment. Mice were i.p. injected with polyIC (4 μg/g) at −10, −8, −6, −4 and −2 days before (Pre-polyIC), or 14, 16, 18, 20 and 22 days after N-Ras/c-Myc (Ras/Myc) transfection via HTVi (Post-polyIC), and mice were sacrificed (SAC) at 4 or 6 weeks (4w or 6w) after oncogene injection, for phenotypic analysis.

(B) Representative macroscopic views and H&E staining of liver sections of control, pre-polyIC and post-polyIC treatments. Magnification: x20; Scale bar: 50 μm.

(C-E) Tumor burdens were calculated by (C) liver weight/body weight (LW/BW) ratios, (D) maximal diameters (mm) or numbers (E) of tumor nodules. Data in (C-E) are presented as means ± SD (n=4–6 per group, *p<0.05, **p<0.01) for any other groups versus the control group.